Genetic erythrokeratoderma

Genetic erythrokeratoderma is a group of rare inherited skin disorders characterized by two main clinical features: well-defined, fixed or migratory red patches (erythema) and thickened, hyperkeratotic plaques on the skin. The condition primarily affects the integumentary system (skin), though in some forms other organ systems may also be involved. The two classic subtypes within this group are erythrokeratoderma variabilis (EKV, also known as Mendes da Costa syndrome) and progressive symmetric erythrokeratoderma (PSEK). In EKV, patients typically present with transient, migratory erythematous patches that can shift in shape and location, along with more stable hyperkeratotic plaques, often on the extremities. In PSEK, symmetric, fixed hyperkeratotic plaques develop progressively, commonly on the limbs, buttocks, and face, with or without accompanying erythema. Onset is usually in infancy or early childhood, with skin changes often appearing within the first year of life. The erythematous patches may be triggered or worsened by temperature changes, emotional stress, or mechanical irritation. Several genetic causes have been identified, most notably mutations in GJB3 and GJB4 (encoding connexin 31 and connexin 30.3, respectively), which are gap junction proteins important for cell-to-cell communication in the epidermis. Some forms have been linked to mutations in other genes as well. The inheritance pattern is most commonly autosomal dominant, though autosomal recessive forms have also been described. There is currently no cure for genetic erythrokeratoderma. Treatment is primarily symptomatic and supportive, focusing on managing skin thickening and dryness. Topical emollients and keratolytic agents (such as urea-based or salicylic acid-based creams) are commonly used. Oral retinoids, such as acitretin, have shown benefit in reducing hyperkeratosis in some patients, though their use requires monitoring for side effects. Regular dermatological follow-up is recommended to manage symptoms and monitor for complications.

Common questions about Genetic erythrokeratoderma